Tuesday, January 19, 2016
JPM 2016: Fear And Loathing In Healthcare From San Francisco
The gloom at the J.P. Morgan 34th annual healthcare conference in San Francisco last week is still thick in the air – and will likely to hover there for a while, as macro issues and falling investor confidence continue to cause problems for the U.S. pharmaceutical and biotech sector. Compare this to last year’s conference, after which the main debate was whether or not we were in a biotech bubble, with many pundits questioning asset valuations. How quickly times change.